| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 25mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| 500mg |
|
||
| Other Sizes |
| Targets |
18:0 PEG-PE does not have a specific biological target or receptor. Its primary function is as a structural component of lipid-based drug delivery systems. The PEG moiety provides a hydrophilic "stealth" coating that reduces opsonization and clearance by the mononuclear phagocyte system, thereby prolonging the circulation time of liposomal formulations. The phospholipid anchor (distearoyl phosphatidylethanolamine, DSPE) integrates into lipid bilayers, anchoring the PEG chains to the nanoparticle surface.
|
|---|---|
| ln Vitro |
In vitro, 18:0 PEG-PE is used to formulate liposomes and nanoparticles for drug delivery. Its presence in liposomal formulations has been shown to reduce uptake by macrophages and increase stability in biological fluids. The compound can also be used for targeted drug delivery when conjugated to targeting ligands, such as biotin or antibodies, via functionalized PEG termini. Specific in vitro activity data (e.g., IC₅₀) are not applicable as it is not a pharmacologically active drug.
|
| ln Vivo |
In vivo, 18:0 PEG-PE is used to formulate liposomal drug delivery systems with extended circulation times. PEGylated liposomes have been shown to have reduced clearance by the reticuloendothelial system and increased accumulation in target tissues via the enhanced permeability and retention (EPR) effect. The compound has been used in cholesterol-free, PEGylated liposomes to study their long-term stability when loaded with hydrophilic drugs like carboplatin. Specific in vivo efficacy data depend on the encapsulated drug.
|
| Enzyme Assay |
A cell-free assay for 18:0 PEG-PE is not applicable as it is not a pharmacologically active compound with a specific target. Its properties are typically characterized by physical methods, such as dynamic light scattering (DLS) to measure particle size, zeta potential to assess surface charge, and transmission electron microscopy (TEM) to visualize liposome morphology. Its ability to form micelles and liposomes can be assessed in buffer solutions.
|
| Cell Assay |
Cellular experiments with 18:0 PEG-PE typically involve evaluating the uptake and cytotoxicity of PEGylated liposomes or nanoparticles in cell lines. For example, fluorescently labeled liposomes containing 18:0 PEG-PE can be used to study cellular internalization and intracellular trafficking. The compound itself is considered biologically inert and is used as a formulation component rather than an active agent. Specific protocols depend on the encapsulated drug or imaging agent.
|
| Animal Protocol |
In vivo animal experiments using 18:0 PEG-PE typically involve the administration of liposomal or nanoparticle formulations containing the compound. For example, PEGylated liposomes loaded with a chemotherapeutic agent can be injected intravenously into tumor-bearing mice to evaluate pharmacokinetics, biodistribution, and antitumor efficacy. The PEGylation is expected to prolong circulation and enhance tumor accumulation. Specific protocols depend on the therapeutic payload and disease model.
|
| ADME/Pharmacokinetics |
18:0 PEG-PE is a formulation excipient and does not have conventional pharmacokinetic (PK) properties as a pharmacologically active drug. Its role in drug delivery is to modify the PK of encapsulated drugs by prolonging circulation time and altering biodistribution. The PEG chain provides steric stabilization, reducing opsonization and clearance. The compound is typically used in liposomal formulations for parenteral administration.
|
| Toxicity/Toxicokinetics |
18:0 PEG-PE is generally considered non-toxic and is widely used in pharmaceutical formulations as an excipient. It has been used in FDA-approved liposomal drug products. As a PEGylated phospholipid, it is well-tolerated in vivo. However, specific toxicity data are not provided in the available sources. The compound is intended for research and pharmaceutical use and is not for direct human consumption as a standalone agent.
|
| References |
|
| Additional Infomation |
18:0 PEG-PE (CAS: 474922-77-5) is a PEGylated phospholipid conjugate used in the formulation of liposomes and lipid nanoparticles for drug delivery. It is also known as mPEG-DSPE or 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-[methoxy(polyethylene glycol)]. The compound self-assembles into micelles or integrates into lipid bilayers, providing a PEG coating that prolongs circulation and reduces immunogenicity. It is a key component in the development of sterically stabilized ("stealth") liposomal formulations. It is not a therapeutic drug itself but a critical excipient in drug delivery systems.
|
| Molecular Formula |
(C2H4O)N.C43H84NO10P.NH3
|
|---|---|
| Exact Mass |
866.636
|
| CAS # |
474922-77-5
|
| Related CAS # |
18:0 mPEG2000 PE ammonium;474922-77-5
|
| PubChem CID |
156593651
|
| Appearance |
White to off-white solid
|
| Hydrogen Bond Donor Count |
3
|
| Hydrogen Bond Acceptor Count |
12
|
| Rotatable Bond Count |
48
|
| Heavy Atom Count |
59
|
| Complexity |
986
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
O=C(NCCOP(O)(OC[C@@H](COC(CCCCCCCCCCCCCCCCC)=O)OC(CCCCCCCCCCCCCCCCC)=O)=O)OCCOC.N.[n]
|
| InChi Key |
KBXRORNJMUHWKT-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C45H88NO11P.H3N/c1-4-6-8-10-12-14-16-18-20-22-24-26-28-30-32-34-43(47)54-40-42(41-56-58(50,51)55-37-36-46-45(49)53-39-38-52-3)57-44(48)35-33-31-29-27-25-23-21-19-17-15-13-11-9-7-5-2;/h42H,4-41H2,1-3H3,(H,46,49)(H,50,51);1H3
|
| Chemical Name |
azane;[3-[hydroxy-[2-(2-methoxyethoxycarbonylamino)ethoxy]phosphoryl]oxy-2-octadecanoyloxypropyl] octadecanoate
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment, avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
